The use of the PD-1/PD-L1 pathway as an immunotherapy in oncological diseases, autoimmune diseases and infectious diseases

Dominika Katarzyna Madras, Agata Agnieszka Rocka, Klaudia Daria Szumna, Patryk Piotr Jasielski, Faustyna Piędel




PD-1 is programmed death receptor 1 belonging to the CD28 family of receptors. Immune cells have this receptor on their surface. PD-L1 allows cancer cells to avoid the host's response. Connection to the PD-1 receptor leads to the death of the immune cell.


The use of PD-1 receptors in the treatment of oncological, autoimmune and infectious diseases.

Abbreviated description of the state of knowledge: 

The development and progression of immunotherapy in recent years has resulted in the approval of five immunotherapy pathways targeting PD-1 (pembrolizumab and durvalumab) or PD-L1 (atezolizumab, nivolumab and avelumab) in patients with progression during or after cisplatin based chemotherapy. The latest updates show that in some types of cancer, positive PD-L1 expression has an effect on treatment effect and qualification. These therapies are used, among others in melanoma, lymphomas, kidney cancer or breast cancer. PD-1 is also used to treat autoimmune and infectious diseases.


Understanding the mechanism of the PD-1/PD-L1 pathway allows to design targeted therapy for individuals. It has been already used in NSCLC treatment program, whether bladder cancer or melanoma. Immunotherapy increases the survival time of patients with advanced stages of cancer. The therapies targeting the PD-1/PD-L1 pathway in autoimmune and infectious diseases are in clinical trials.


programmed death receptor-1 (PD-1); programmed death receptor ligand-1 (PD-L1); immunotherapy; oncology; autoimmunology; infectious diseases

Full Text:



Wang X, Yang X, Zhang C Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650.

Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure. 2017 Aug 1;25(8):1163-1174

Mengjia Song, Xinfeng Chen, Liping Wang, Yi Zhang.Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chin J Cancer Res. 2018 Apr; 30(2): 157–172.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Mar;44:51-60.

Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017 Mar;35(7):785-792.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016 Jul;28(4):254-63.

Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019 Aug;25(8):1243-1250.

Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018 Jan 17.

Pierrard J, Petit B, Lejeune S, Seront E. Isolated adrenocorticotropic hormone (ACTH) deficiency and Guillain-Barré syndrome occurring in a patient treated with nivolumab. BMJ Case Rep. 2019 Aug 21;12(8).

Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep. 2020 Mar 17;22(4):15.

Celli R, Kluger HM, Zhang X. Anti-PD-1 Therapy-Associated Perforating Colitis. Case Rep Gastrointest Med. 2018 May 31;2018:3406437.

Imblum BA, Baloch ZW, Fraker D, LiVolsi VA. Pembrolizumab-Induced Thyroiditis. Endocr Pathol. 2019 Jun;30(2):163-167.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-76.

Weber JS, Postow M, Lao CD, Schadendorf D. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Oncologist. 2016 Oct;21(10):1230-1240.

Petrova V, Arkhypov I, Weber R, Groth C, Altevogt P, Utikal J et al. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. Int J Mol Sci. 2020 Mar 30;21(7).

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71.

Lenfant L, Aminsharifi A, Seisen T, Rouprêt M. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. Curr Opin Urol. 2020 May;30(3):428-440.

De Maeseneer DJ, Delafontaine B, Rottey S. Checkpoint inhibition: new treatment options in urologic cancer. Acta Clin Belg. 2017 Feb;72(1):24-28.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322.

Xiaomo Wu, Zhongkai Gu, Yang Chen, Borui Chen, Wei Chen, Liqiang Weng, et al. Application of PD-1 Blockade in Cancer Immunotherapy Comput Struct Biotechnol J. 2019; 17: 661–674.

Chandrasekaran D, Sundaram S, N K, R P. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2951-2957.

Cimadamore A, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay. Curr Drug Targets. 2020 Mar 24.

Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney Int Rep. 2016 Sep 21;2(1):108-123.

Numakura K, Horikawa Y, Kamada S, Koizumi A, Nara T, Chiba S, Kanda S, Saito M, Narita S, Inoue T, Shimoda N, Habuchi T. Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis. Mol Clin Oncol. 2019 Sep;11(3):320-324.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290.

Xiaomo Wu, Zhongkai Gu, Yang Chen, Borui Chen, Wei Chen, Liqiang Weng et al. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019; 17: 661–674.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 Jan 29;6(1):9.

Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. Cancer Treat Rev. 2018 Jan;62:39-49.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986.

Hu J, Shang Y, Shi X, Zhang S, Shi J, Yao M et al. Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancer. Oncol Rep. 2020 Mar 23.

Praveen Vikas, Nicholas Borcherding, Weizhou Zhang. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018 Dec 10;10:6823-6833.

Wang Xinran, Yueping Liu. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathology - Research and Practice Volume 216, Issue 3, March 2020, 152802.

Hitomi Mori, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget. 2017; 8:15584-15592.

Reddy SM, Carroll E, Nanda R. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020 Mar;20(3):151-158.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108-2121.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M2,3,4,5,6,7, Damotte D et al. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget. 2017 Jul 4;8(27):44960-44975.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9.

Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018 Jan 4;131(1):68-83.

Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol. 2017;410:75-97.

Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014 Jul;290(1):72-9.

Kooij G, Derada Troletti C, Leuti A, Norris PC, Riley I, Albanese M et al.Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica. 2019 Nov 28. pii: haematol.2019.219519.

Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X,et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One. 2018 Feb 28;13(2):e0192704.

Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, et al. PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.Front Immunol. 2018 Aug 31;9:1995.

Shu CC, Wang JY, Wu MF, Lai HC, Chiang BL, Yu CJ. Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease. Tuberculosis (Edinb). 2018 May;110:7-14.

Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, et al. PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis.Front Immunol. 2018 Aug 31;9:1995.

Wuyts L, Janssens A, Vonghia L, Michielsen P, Raskin J, Driessen A, et al Nivolumab and anti-HCV activity, a case report. Acta Clin Belg. 2020 Mar 17:1-5.

Mathur P, Emmanuel B, Sneller M, Zhang X, Poonia B, Kottilil S. Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis. J Med Virol. 2018 May;90(5):936-941.

Zahran AM, Hetta HF, Rayan A, Eldin AS, Hassan EA, Fakhry H, et al. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. Cancer Immunol Immunother. 2020 Mar 13.

Che YM, Zhang Y, Li M, Li XP, Zhang LL. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis. J Cell Biochem. 2018 Apr;119(4):3044-3057.

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48


Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism